Press "Enter" to skip to content

New patent for NOVO drug RYBELSUS

0
Copyright © DrugPatentWatch. Originally published at New patent for NOVO drug RYBELSUS

Annual Drug Patent Expirations for RYBELSUS
Annual Drug Patent Expirations for RYBELSUS

Rybelsus is a drug marketed by Novo and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug.

RYBELSUS drug price trends.

Drug patent litigation for RYBELSUS.

This drug has one hundred and eighteen patent family members in thirty countries.

The generic ingredient in RYBELSUS is semaglutide. One supplier is listed for this compound. Additional details are available on the semaglutide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at New patent for NOVO drug RYBELSUS
    Find your next blockbuster

    Get accurate and timely intelligence — in just a few clicks

    ✓ Free trial

    ✓ No credit card

     

    DrugPatentWatch - Make Better Decisions